Table 4. Validation of prognostic biomarker for each AJCC stage melanoma in additional melanoma patients#.
| Factor | AJCC I (N = 18)* | AJCC II (N = 30) | AJCC III (N = 27) | AJCC IV (N = 12) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | |
| Age | 0 | NA | 1 | 3.54 | 0.31–38.4 | 0.30 | 0.70 | 0.23–2.16 | 0.54 | 1.73 | 0.34–8.81 | 0.51 |
| Gender | 0 | NA | 1 | 0.43 | 0.08–2.48 | 0.35 | 2.59 | 0.54–12.5 | 0.24 | 0.19 | 0.02–2.04 | 0.17 |
| Thickness | 0 | NA | 1 | 12.1 | 1.10–132 | 0.04 | - | - | - | - | - | - |
| Ulceration | 0 | NA | 1 | 3.86 | 0.69–21.8 | 0.13 | - | - | - | - | - | - |
| BRAF | 0 | NA | 1 | - | - | - | - | - | - | - | - | - |
| MMP2 | - | - | - | 23.1 | 2.02–264 | 0.012 | - | - | - | - | - | - |
| P27 | - | - | - | - | - | - | 1.74 | 0.56–5.39 | 0.34 | 4.30 | 0.61–30.3 | 0.14 |
#
In addition to the discovery cohort, which has data available for all 6 candidate biomarkers; there are additional patients, for whom data is available for specific markers, but not for all 6 markers.
*
No patient out of the 18 in stage I died, thus the Cox regression analysis could not be executed.